IBM is a buy on improving fundamentals and a quantum computing catalyst. Revenue grew from $57.4B in 2021 to $67.5B in 2025, with gross margins expanding from 54.9% to 59.5% and diluted EPS surging to $11.17. The recent $1 billion CHIPS Act funding for a U.S. quantum chip foundry provides a high-visibility growth narrative, while the stock's RSI of 63 and bullish MACD crossover suggest positive momentum despite trading below the 200-day MA. Free cash flow of $11.6B comfortably services the $67.2B debt load, and the valuation is reasonable at 22.2x earnings versus a peer median of 22.6x.
Elevated Leverage
Total debt of $67.2B is more than double stockholders' equity of $32.6B, and rising rates could pressure interest coverage if FCF declines.
Quantum Execution Risk
The $1B government grant is a long-term bet; commercial quantum revenue may take years to materialize, and the stock's double-digit jump may have priced in near-term optimism.
Competitive Pressure
Peers like Accenture (PE 14.4x, EV/EBITDA 9.0x) and EPAM (PE 14.3x, EV/EBITDA 6.8x) trade at lower multiples, and IBM's consulting segment faces intense competition.
Macro Sensitivity
IT services and consulting revenue could slow if enterprises cut discretionary spending in a downturn, impacting the 2025 revenue growth trajectory.